1. The Penetration of Biosimilars in the US Will Vary Across Different Biological Classes
The volume penetration of biosimilars in the US will strongly depend upon the complexity of
the molecule, the patient pool that it caters and the extent of savings it brings to payers and
providers
IMARC Group, one of the world’s leading life science research and advisory firms, finds that as
a result of their higher molecule complexity, higher cost of manufacturing and lower number
of biosimilar competitors (2-5 in case of biosimilars as against up to 9-10 in small molecule
generics); the average volume penetration of biosimilars will be significantly lower than that
of small molecule generics. The study also expects the volume penetration of different
biological classes to vary from one another depending upon the following factors:
Biosimilars which are more complex will have a lower penetration compared to those
that are less complex.
Volume penetration would also depend upon how lucrative the branded biological drug
is for biosimilar volume erosion. Drugs that have achieved blockbuster sales and show a
good potential for future growth represent a good target for biosimilar companies. Payers
and Providers are also expected to promote biosimilars which enable them to achieve
substantial cost savings.
Trends of in-market biosimilars show that penetration rates also depend upon the
targeted indication and patient pool for biosimilar drugs. Drugs which are targeted
towards more sensitive patients (i.e. children) are expected to have a lower penetration
rate as physicians will not prescribe these drugs until they have significant long term
safety and efficacy data. Similarly, indications where the benefits and side effects of the
drug are not immediately visible and take a long time to identify (i.e. hormone deficiency)
will have a lower share than indications where the side effects and benefits are easily
visible (i.e. Anaemia).
The penetration of various biosimilars would vary across different countries. The volume
penetration of small molecule generics in the US has been found to be higher than that
of major European markets. As a result, we expect biosimilar penetration in the US to be
higher than major European markets.
imarc© 1

2. IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast:
A Focus on the US (2011-2020)” provides an analytical and statistical insight into the US
biosimilar market. The study, that has been undertaken using desk-based as well as
qualitative primary research, provides and draws upon analysis of six aspects of the US
biosimilar market.
Key Aspects Analyzed:
Evaluating the Current Market Landscape of Biosimilars:
Identification of currently marketed biosimilars and their historical performance
Identifying the reasons for the slow uptake of currently marketed biosimilars
Analyzing historical data to formulate conclusions on the future growth and market
trends of biosimilars
Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:
Analyzing historical time series data on price, volume and sales erosion in the US &
Europe
Analyzing previous models and assumptions on price and volume erosion caused by
biosimilars
Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by
small molecule generics
Evaluating and comparing price, volume and sales erosion by biosimilars across various
biological classes
Evaluating the Market Potential of Biosimilars Across Various Molecules:
Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa
(Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog),
Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon
Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab
(Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab
(Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and
Natalizumab (Tysabri).
imarc© 2

3. Focus of the Analysis for Each Molecule:
Historical background and overview
Historical brand sales
Patent position
Competing products
Biosimilars in pipeline
Brand and biosimilar sales forecasts
Evaluating the Sales of Biosimilars across Various Indications:
Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and
Growth Deficiency
Focus of the Analysis for Each Indication:
Historical brand sales
Brand and biosimilar sales forecasts
Indication wise breakup of molecules
Evaluating the Biosimilar Competitive Landscape:
Identifying branded biological manufacturers that expect the highest amount of erosion
from biosimilars
Identifying biosimilar manufacturers and their pipelines
Understanding the Current Legislation on Biosimilars:
An insight into the Biologics Price Competition and Innovation Act
An insight into the key biosimilar issues that still remain unaddressed
Interchangeability and Substitutability
Data Exclusivity
Statutory provisions for dealing with patent litigations
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-425-6531
IMARC Group North America
imarc© 3

4. Email: america@imarcgroup.com
Phone: +1-631-791-1145
To know more please visit: http://www.imarcgroup.com/
Key words
Biosimilar market, biosimilar industry, follow-on biologics market, biogenerics market, us biosimilar
market, biosimilar volume penetration rate
imarc© 4